FMP
Replimune Group, Inc.
REPL
NASDAQ
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
10.14 USD
-0.22 (-2.17%)
Dr. Sushil Patel Ph.D.
Healthcare
Biotechnology
NASDAQ
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
0001737953
US76029N1063
76029N106
500 Unicorn Park Drive
781 222 9600
US
331
Jul 20, 2018
Dr. Konstantinos Xynos M.B.A., M.D., Ph.D.
Chief Medical Officer
668.69k
1967
Ms. Emily Luisa Hill
Chief Financial Officer
593.05k
1980
Mr. Christopher Sarchi
Chief Commercial Officer
0
1969
Mr. Andrew Schwendenman
Chief Accounting Officer & Treasurer
0
1976
Dr. Robert Coffin Ph.D.
Founder, Chief Scientist & Director
785.89k
1965
Mr. Philip Astley-Sparke F.S.A.
Executive Chairman
960.52k
1971
Dr. Sushil Patel Ph.D.
Chief Executive Officer & Director
665.05k
1971
Mr. Paul Bullock
Chief Manufacturing Officer & Framingham...
0
N/A
As of December 31, 2024, the total employee count stands at 331, with compensation values reflecting the last fiscal year ending on that date. Pay encompasses salary, bonuses, etc., All figures are in USD.